1799.TWO Easywell Biomedicals Inc.

Healthcare Health Care Equipment & Supplies Taiwan OTC Exchange
25.05 TWD
Close of Nov 5, 2026
24.00 44.90
Market cap
TWD 3.12B
P/E
-
P/B
4.46x
ROE
2.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1799.TWO undervalued?

Graham number

The Graham number of Easywell Biomedicals Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Easywell Biomedicals Inc. fundamental analysis

No fundamental analysis for Easywell Biomedicals Inc. yet.

Easywell Biomedicals Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Easywell Biomedicals Inc.

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-0…

Full company profile